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THE DIABETES PREVENTION
TRIAL–TYPE 1S TUDY GROUP
OBJECTIVE — We studied the incidence of dysglycemia and its prediction of the develop-
ment of type 1 diabetes in islet cell autoantibody (ICA)-positive individuals. In addition, we
assessed whether dysglycemia was sustained.
RESEARCH DESIGN AND METHODS — Participants (n  515) in the Diabetes Pre-
vention Trial–Type 1 (DPT-1) with normal glucose tolerance who underwent periodic oral
glucose tolerance tests (OGTTs) were followed for incident dysglycemia (impaired fasting glu-
cose, impaired glucose tolerance, and/or high glucose levels at intermediate time points of
OGTTs). Incident dysglycemia at the 6-month visit was assessed for type 1 diabetes prediction.
RESULTS — Of 515 participants with a normal baseline OGTT, 310 (60%) had at least one
episode of dysglycemia over a maximum follow-up of 7 years. Dysglycemia at the 6-month visit
was highly predictive of the development of type 1 diabetes, both in those aged 13 years (P 
0.001) and those aged 13 years (P  0.01). Those aged 13 years with dysglycemia at the
6-month visit had a high cumulative incidence (94% estimate by 5 years). Among those who
developed type 1 diabetes after a dysglycemic OGTT and who had at least two OGTTs after the
dysglycemicOGTT,33of64(52%)revertedbacktoanormalOGTT.However,26(79%)ofthe
33 then had another dysglycemic OGTT before diagnosis.
CONCLUSIONS — ICA-positive individuals with normal glucose tolerance had a high in-
cidenceofdysglycemia.IncidentdysglycemiainthosewhoareICApositiveisstronglypredictive
oftype1diabetes.Childrenwithincidentdysglycemiahaveanespeciallyhighrisk.Fluctuations
in and out of the dysglycemic state are not uncommon before the onset of type 1 diabetes.
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T
here is increasing evidence that im-
paired glucose tolerance (IGT) is a
predictor and common precursor of
type 1 diabetes (1–3). Still, little is known
about the incidence of IGT and other
forms of dysglycemia in individuals who
have pancreatic autoantibodies and nor-
mal glucose tolerance. In addition, there
is no information about the risk of type 1
diabetes when dysglycemia occurs in
those individuals. Moreover, it is not
known whether dysglycemia is sustained
once it occurs.
We used data from the Diabetes Pre-
vention Trial–Type 1 (DPT-1) (4,5) to ex-
aminethesequestions.InadditiontoIGT,
impaired fasting glucose (IFG) and high
glucose values at intermediate times (be-
tweenfastingand2h)duringoralglucose
tolerance tests (OGTTs), termed indeter-
minate glycemia (INDET), were included
as other forms of dysglycemia in the anal-
yses. Glucose levels at intermediate times
have been shown to be predictive of type
1 diabetes (6,7).
Information regarding the incidence
of these various forms of dysglycemia and
their prediction of type 1 diabetes should
be helpful for understanding the patho-
genesis and natural history of type 1 dia-
betes. Such information should also be
useful for improving type 1 diabetes pre-
vention trials.
RESEARCH DESIGN AND
METHODS— There were a total of
711 participants in the parenteral (n 
339) and oral (n  372) insulin DPT-1
trials. All were islet cell autoantibody
(ICA)-positive relatives of type 1 diabetic
patients.Greaterthana50%5-yearriskof
developing type 1 diabetes was required
for eligibility for the parenteral insulin
trial. Individuals were deemed to have a
50%5-yearriskiftheﬁrst-phaseinsulin
response (FPIR) on an intravenous glu-
cose tolerance test was below a deﬁned
threshold and/or there were OGTT ab-
normalities (IFG, INDET, or IGT). Those
withoutmetaboliccriteriabutpositivefor
insulinautoantibodieswereconsideredto
have a 26–50% 5-year risk and were eli-
gible for the oral insulin trial. There was
no overall treatment effect in either trial.
Theanalysesincluded515participantsin
the parenteral (n  168) and oral trials
(n  347). All had normal OGTTs before
trial entry, at least one nondiabetic OGTT
after randomization, and no missing val-
ues (n  6). Individuals excluded were
somewhat older (15.4  10.6 vs. 13.3 
9.1years,P0.01).Therewasalmostno
differenceinsex(excluded:58%male;in-
cluded: 56% male).
Procedures
Participants in the parenteral insulin trial
intervention group received recombinant
human ultralente insulin, whereas those
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received recombinant human insulin
crystals. OGTTs were performed at
6-month (3 months) intervals in both
trials. The dose of oral glucose was 1.75
g/kg (maximum, 75 g carbohydrate).
Blood samples were obtained for plasma
glucose in the fasting state and at 30, 60,
90, and 120 min. In most individuals,
type 1 diabetes was diagnosed at routine
visits. Those with OGTTs in the diabetic
range were asked to return for conﬁrma-
tion by another OGTT unless this was
clinically contraindicated. If the second
OGTT was not conﬁrmatory, participants
continued to be followed at 6-month
intervals.
Laboratory measures
Methodologiesforassessingautoantibody
positivity in DPT-1 have been described
previously (8). ICAs were determined by
indirect immunoﬂuorescence, and insu-
lin autoantibodies were measured by a
competitive ﬂuid-phase radioassay.
Plasma glucose levels were measured by
the glucose oxidase method. Insulin was
measured by radioimmunoassay.
Data analysis
The t test and 
2 test were used for simple
comparisons, and the log-rank test was
usedtocomparethedistributionsofevent
times between groups. The Cox propor-
tional hazards regression model was used
for assessing type 1 diabetes associations
overtime.Kaplan-Meiercurveswereused
to obtain cumulative incidence estimates
oftype1diabetesovertime.Incidentdys-
glycemia was deﬁned as the ﬁrst dysgly-
cemic OGTT that occurred.
Glucose tolerance abnormalities were
deﬁned as follows: IFG, fasting glucose
value of 100–125 mg/dl; INDET, 30-,
60-, and/or 90-min glucose value 200
mg/dl; and IGT, 2-h glucose value 140–
199 mg/dl. The thresholds for diabetes
were a fasting glucose value 126 mg/dl
and/or a 2-h glucose value 200 mg/dl.
Unconﬁrmed OGTTs in the diabetic
rangewereexcluded(n81[2.8%]ofall
OGTTs performed during follow-up)
from the analysis. The FPIR was deﬁned
as the sum of insulin levels at the 1st and
3rd min of the intravenous glucose toler-
ance test. An FPIR less than the 10th per-
centile according to age norms was
considered below threshold. Of those an-
alyzed, 35% were below this threshold.
SAS (version 9.1.3) was used for the
analyses. All P values are two-sided.
RESULTS— Of the 515 DPT-1 partic-
ipants with normal glucose tolerance at
baseline who were studied, 56% were
male. The mean  SD age at baseline was
13.3  9.1 years.
Over a maximum follow-up of 7.0
years (mean  SD 2.3  1.6 years), dys-
glycemia occurred in 310 (60%) of the
515 participants, with 2- and 5-year esti-
matesof41and73%.Inproportional
hazards models, there were no associa-
tions of dysglycemia with either age or
sex. Dysglycemia occurred in 199 of 330
(60%) of those aged 13 years, with 2-
and 5-year estimates of 44 and 73%, re-
spectively. Of those aged 13 years, 111
of 185 (60%) developed dysglycemia,
with 2- and 5-year estimates of 36 and
72%, respectively. In a proportional haz-
ards model, there was no association be-
tween incident dysglycemia and an FPIR
below threshold.
Distributions of the speciﬁc abnor-
malities for the ﬁrst occurrence of dysgly-
cemia are shown in Table 1, overall and
according to 13 and 13 years age cat-
egories. Overall, IGT alone (43%) oc-
curred much more frequently than either
IFG alone (16%) or INDET alone (17%).
Sixty-ﬁve percent of the participants de-
veloped IGT alone or in combination.
There were no signiﬁcant differences in
the proportions of IFG, INDET, and IGT
between those aged 13 and 13 years.
Whereas the proportions of IFG and
INDET were similar between female
and male participants (IFG 24 vs. 25%
and INDET 34 vs. 41%, respectively), the
proportionwithIGTwashigherinfemale
participants (75 vs. 58%, P  0.01).
The risk for the development of sub-
sequent type 1 diabetes after the occur-
rence of dysglycemia was examined
among those individuals (n  484) who
had a nondiabetic OGTT at the 6-month
visit (6  3 months). Over a maximum
follow-up of 6.7 years (2.9  1.6 years)
from the 6-month visit, 131 (27%) devel-
opedtype1diabetes.Inproportionalhaz-
ards models (Table 2), those with a
dysglycemic OGTT at the 6-month visit
had a much greater risk for the subse-
quent development of type 1 diabetes
than those with a normal OGTT (53 of 97
vs. 78 of 387; P  0.001). When the data
were stratiﬁed according to age 13 and
13years,theassociationbetweentype1
diabetesanddysglycemiaat6monthswas
apparent in both groups (P  0.001 for
age 13 years and P  0.01 for age 13
years). The increased progression to type
1 diabetes among those with dysglycemia
at the 6-month visit is evident in the cu-
mulativeincidencecurvesinFig.1.When
IGTwasusedasamarker,40of63(63%)
developed type 1 diabetes. The 4-year es-
timate for IGT was 72%, whereas that for
dysglycemia was 65%.
Among those who also had a normal
OGTTat6months,therewasstillastrong
Table 1—Distribution of glucose tolerance abnormalities for the ﬁrst occurrence of dysglyce-
mia among participants
All 13 years 13 years
IFG alone 50 (16.1) 27 (13.6) 23 (20.7)
INDET alone 51 (16.5) 33 (16.6) 18 (16.2)
IGT alone 133 (42.9) 87 (43.7) 46 (41.4)
IFG and INDET 7 (1.9) 5 (2.5) 2 (1.7)
IFG and IGT 9 (2.9) 8 (4.0) 1 (0.9)
IGT and INDET 49 (16.1) 35 (17.6) 14 (12.6)
IFG, IGT, and INDET 11 (3.5) 4 (2.0) 7 (6.3)
Total 310 199 111
Data are n (%).
Table2—Predictionoftype2diabetesaccordingtothepresenceofincidentdysglycemiaatthe
6-month visit
Age n
Type 1 diabetes/total
HR (95% CI)* Dysglycemic Normal
All 484 53/97 78/387 5.2 (3.7–7.5)†
13 years 312 44/67 60/245 5.4 (3.6–8.1)†
13 years 172 9/30 18/142 4.1 (1.8–9.3)‡
*With an adjustment for age. †P  0.001; ‡P  0.01.
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dysglycemia occurring at 1 year (19 of 43
vs. 48 of 291; P  0.001), even with the
shorter follow-up (maximum: 5.5 years).
Sex was not predictive of type 1 diabetes
either at 6 months or at 1 year.
In an analysis limited to only those
individuals with dysglycemia at 6
months, type 1 diabetes was inversely re-
lated to age (P  0.001) in a proportional
hazards model. This ﬁnding is evident in
Fig. 2, in which the risk estimate for type
1diabeteswasmuchhigherforthoseaged
13 years (94 vs. 40% by 5 years). The
hazard ratio (HR) was 3.3 (95% CI 1.6–
6.7; P  0.001). There were 24 partici-
pants aged 13 years with incident
dysglycemia at 6 months that persisted
at 1 year. Of these, 18 developed type 1
diabetes (75%) with a maximum fol-
low-up of 4.5 years. Of the 15 children
aged 13 years with incident IGT that
persisted at 1 year, 14 (93%) developed
type 1 diabetes.
Among the 515 individuals studied,
136 developed type 1 diabetes. Of the
136, 78 (57%) had a minimum of three
Figure 1—Shown are cumulative incidence curves for the subsequent development of type 1 diabetes according to whether dysglycemia occurred at
the 6-month visit. The actual proportion of those developing type 1 diabetes is shown for each curve. The cumulative incidence was signiﬁcantly
greater when dysglycemia occurred at the 6-month visit.
Figure 2—Shown are cumulative incidence curves for the development of type 1 diabetes according to whether participants were aged 13 or 13
years among those who were dysglycemic at the 6-month visit. The cumulative incidence was signiﬁcantly higher in the younger age-group, with an
estimate of 94% by 5 years in those children.
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(95%) had at least one dysglycemic
OGTT. Among the 275 participants with
a minimum of three visits who did not
developtype1diabetes,152(55%)hadat
least one dysglycemic OGTT.
The occurrence of a single glucose
tolerance abnormality at 6 months was
assessed for the prediction of type 1 dia-
betes. Type 1 diabetes did not occur sig-
niﬁcantly more frequently in individuals
with IFG (5 of 15; P  0.216) when they
werecomparedwiththosewhohadanor-
mal OGTT at the 6-month visit (78 of
387). However, in a proportional hazards
model with age included as a covariate,
IFG was predictive (P  0.009). Type 1
diabetes occurred signiﬁcantly more fre-
quently in individuals with INDET alone
(8of17;P0.008)orwithIGTalone(19
of 36; P  0.001) at the 6-month visit
when they were compared with those
withnormalOGTTs.Inproportionalhaz-
ards models with age as a covariate, the
associations persisted (P  0.002 for
INDET and P  0.001 for IGT).
To assess whether dysglycemia was
sustained once it occurred, we studied 64
participants who developed type 1 diabe-
tes after dysglycemia had occurred and
whohadatleasttwoOGTTsafterthedys-
glycemic OGTT. Of these, 33 (52%) re-
verted back to a normal OGTT. However,
26 of the 33 (79%) then had another dys-
glycemic OGTT before diagnosis.
CONCLUSIONS — This study is
uniqueinthatitexaminedtheoccurrence
of dysglycemia in autoantibody-positive
individuals who had preexisting normal
glucose tolerance. The incidence of dys-
glycemia was very high in both the
youngerandolderage-groups.Thedistri-
bution of the forms of dysglycemia was
similar between the age-groups, and IGT
wasthemostcommontype.Thedataalso
showed that incident dysglycemia was
strongly predictive of type 1 diabetes, in
both younger and older individuals.
There is no prior information avail-
able regarding the incidence of dysglyce-
mia and its prediction of type 1 diabetes
in autoantibody-positive individuals with
antecedent normal glucose tolerance.
However,IGThasbeenfoundtobeapre-
dictor and precursor of type 1 diabetes
(1–3). In addition, fasting glucose levels
and glucose levels at various OGTT time
pointshavebeenfoundtobepredictiveof
type 1 diabetes (7,9).
The data in this report indicate that
among autoantibody-positive individuals
there is a high likelihood of dysglycemia
occurring at some point before the onset
of type 1 diabetes. The occurrence of at
least one episode of dysglycemia in those
who developed type 1 diabetes was very
high. Although the occurrence of dysgly-
cemia was much lower among those who
didnotdeveloptype1diabetes,itwasstill
substantial. This ﬁnding suggests that
some of the latter could have developed
type 1 diabetes with more extended
follow-up.
IGT occurring alone appears to be
highly predictive of type 1 diabetes. Al-
though the extent to which either IFG or
INDET occurring alone predicts type 1
diabetes is difﬁcult to gauge because of
the small numbers, each of those dysgly-
cemia abnormalities occurring singly at 6
months was predictive of type 1 diabetes
with age as a covariate. The data suggest
that INDET can indeed be used as a pre-
dictor of type 1 diabetes in addition to
the more traditional indicators of
dysglycemia.
The risk for type 1 diabetes at 4 years
was somewhat higher for IGT than for
dysglycemia. However, the number who
developed dysglycemia at 6 months was
much greater (97 vs. 63). In choosing cri-
teria for entry into prevention trials, both
of these ﬁndings need to be taken into
account. It appears that the ultimate de-
cision for the criteria to be used rests on
the nature of the speciﬁc prevention trial.
In the overall analyses there was a
lack of inﬂuence of age on the occurrence
of dysglycemia. However, among those
with dysglycemia, age was a strong pre-
dictor of type 1 diabetes. There is no pre-
viousinformationregardingthesespeciﬁc
associations.Althoughthecutoffatage13
wasarbitrary,itservedtodemonstratethe
inﬂuence of age.
The data indicate that even among
those who ultimately develop type 1 dia-
betes, dysglycemia is not necessarily sus-
tained. Moreover, it appears that even
after glucose levels normalize, dysglyce-
mia tends to recur before the diagnosis of
diabetes. This ﬁnding suggests that there
are ﬂuctuations at an undetermined fre-
quency between the normal and dysgly-
cemic states before the onset of type 1
diabetes. The recurrence of dysglycemia
suggests the possibility that dysglycemia
couldhaveoccurredbeforestudyentryin
some individuals.
Because this study was based on a
population of ICA-positive relatives,
some selected on the basis of an FPIR be-
low threshold and some selected on the
basis of insulin autoantibody positivity,
theﬁndingsmaynotnecessarilyfullygen-
eralize to other populations. In addition,
there was limited information regarding
IFG and INDET occurring alone.
The ﬁndings in this report have sig-
niﬁcant implications with regard to in-
creasing the efﬁciency of prevention trials
fortype1diabetes.Becausethedatashow
that dysglycemia will occur in an appre-
ciable percentage of autoantibody-
positive individuals whose initial
screening is negative for dysglycemia, re-
peating OGTTs in those individuals
should increase the yield of potential
high-riskparticipants.Moreover,because
children aged 13 years with incident
dysglycemiahaveaveryhighriskfortype
1 diabetes (94% 5-year estimate despite
the variability of dysglycemia), dysglyce-
mia could possibly be used as an early
indicator of efﬁcacy in prevention trials
forthosewithnormalglucosetoleranceat
baseline.
The pathogenetic development of
type 1 diabetes appears to be an ongoing
process (10,11) with an initial immuno-
logicinsultto-cellsfollowedbyprogres-
sive metabolic deterioration before and
after diagnosis (12–15). Therefore, from
both clinical and research perspectives, it
may be advantageous to identify individ-
uals as early as possible in this process.
The very high likelihood that autoanti-
body-positive children will develop type
1 diabetes within 5 years after the occur-
rence of dysglycemia suggests that the
earlieridentiﬁcationofthediseaseisadis-
tinct possibility.
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